v3.26.1
License, collaboration and commercial agreements - Pfizer, Inc. (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Jul. 11, 2012
Apr. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
License, collaboration and commercial agreements            
Intangible asset     $ 17,123   $ 17,123  
Interest expense     $ 360 $ 212 $ 743 $ 404
Pfizer            
License, collaboration and commercial agreements            
One-time cash payment $ 1,500          
Shares issued 16,001          
Intangible asset   $ 15,000        
Interest expense   $ 500        
Royalty obligations term   10 years        
Pfizer | Achievement of FDA approval            
License, collaboration and commercial agreements            
Potential milestone payments   $ 7,500        
Pfizer | Achievement of FDA approval anniversary            
License, collaboration and commercial agreements            
Potential milestone payments   8,000        
Pfizer | Achievement of certain development and commercialization milestones            
License, collaboration and commercial agreements            
Potential milestone payments   2,000        
Pfizer | Achievement of certain sales milestones            
License, collaboration and commercial agreements            
Potential milestone payments   $ 110,000